Phase 2 N=60 Cetuximab, Paclitaxel, Carboplatin & Radiation for Esoph, Gastroesoph & Gastric Cancer
Esophageal Cancer · Gastric Cancer
Primary: Reponse Rate at Time of Surgery by Tissue — 40 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=8 Translation of Colorectal Cancer Screening Guidelines to Practice: A System Intervention
Colorectal Cancer
Primary: Percent of Patients Receiving GI Consult for FOBT+ Results — 39; 47; 64; 51 percent patients receiving GI consult
N/A N=1,855 The Colorectal Breath Analysis (COBRA) Study
Colorectal Cancer · Colorectal Polyps · Colorectal Adenocarcinoma
Primary: Determine the Diagnostic Accuracy of the Proposed Breath Test for Detection of Colorectal Cancer in All Patients — 79; 86 percentage of true cases
Phase 2 N=13 Genistein in Treatment of Metastatic Colorectal Cancer
Colon Cancer · Rectal Cancer · Colorectal Cancer
Primary: Number of Adverse Events — 250; 119; 24; 0 events
N/A N=5,970 Increasing Colorectal Cancer Screening in a Safety-net Health System With a Focus on the Uninsured: Benefits and Costs
Colorectal Cancer
Primary: Colorectal Cancer Screening Participation, Defined as Completion of a Guaiac or Immunochemical Stool Occult Blood Test, Colonoscopy, Sigmoidoscopy, or Barium Enem…
N/A N=563 An Observational Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer, Colon Cancer in the Adjuvant Setting, Advanced Gastric Cancer or Breast Cancer
Breast Cancer, Colorectal Cancer, Gastric Cancer
Primary: Number of Participants With Routine Clinical Use of Capecitabine as Per the Line of Treatment — 220; 176; 89; 78 Participants
N/A N=265 Colorectal Cancer: Screening vs. Non-Screening
Colorectal Cancer · Screening
Primary: Colorectal Cancer Stage (pTNM) — 46; 85 Participants
N/A N=801 U01 CRC Project for Vietnamese Americans
Colorectal Cancer
Primary: Colorectal Cancer Screening Rate — 333; 162 Participants
Phase 1 N=25 Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects
Metastatic Gastric Cancer · Metastatic Breast Cancer · Metastatic Colorectal Cancer
Primary: Number of Participants With Treatment-emergent Adverse Events — 1; 0; 3; 3 Participants
Phase 2 N=18 Neo-adjuvant Chemotherapy in Locally Advanced Gastric Cancer
Stage T3-4NxM0 Gastric Cancer
Primary: Number of Participants With Pathological Response — 0; 4; 8; 3 Participants
N/A N=120 Healthy Eating for Colon Cancer Prevention
Colon Cancer
Primary: Adherence to Dietary Goals — 89; 85 percentage of participants meeting goals
N/A N=41,193 Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Colorectal Cancer
Primary: FIT Completion — 10.4; 13.9 Model based percentage of participants — p=.05
N/A N=100 Screen to Save: A Colorectal Cancer Educational Intervention
Colorectal Cancer
Primary: Change in Knowledge Related to Colorectal Cancer Risk, Prevention, and Screening — 1 score on a scale — p=0.0001
Phase 2 N=20 Cellular Immune Augmentation in Colon and Rectal Cancer
Colon Cancer · Rectal Cancer
Primary: Participants Exhibiting Immune Response — 11 Participants
Phase 2 N=150 Docetaxel+Oxali+/-Cetux Met Gastric/GEJ
Gastric Cancer Adenocarcinoma Metastatic
Primary: Progression-free Survival — 4.7; 5.1 months
N/A N=1,111 Helping Patients and Providers Make Better Decisions About Colorectal Cancer Screening
Cancer Screening Tests
Primary: Number of Participants Who Completed Colorectal Cancer Screening — 110; 95; 113; 113 Participants
Phase 2 N=26 Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction (GEJ) Tumors
Stomach Neoplasms · Esophageal Neoplasms
Primary: Overall Response Rate (ORR) — 39.1 percentage of participants
N/A N=1,612 Improving Comprehensive Cancer Screening Among Vulnerable Patients Using Patient Navigation
Patient Compliance
Primary: Percentage of Cancer Screening Tests Completed - Intention to Treat — 10.2; 6.8; 14.7; 11.0 percentage of screening visits completed — p=<0.001
Phase 2 N=79 Aspirin in Preventing Colorectal Cancer in Patients at Increased Risk of Colorectal Cancer
Colon Cancer · Precancerous Condition · Rectal Cancer
Primary: Change of a Spectral Biomarker for Colonic Carcinogenesis (Called Spectral Slope or SPEC) From Baseline to 3 Months. — 40.72; 37.54; 43.45; 37.52 micron^-1 — p=0.11
N/A N=250 Precision-Based Magnesium Trial
Colorectal Cancer
Primary: TRPM7 Expression Level in Colorectal Mucosa by Mg Treatment Compared With Placebo — 0.03; 0.08; -0.09; -0.11 log (arbitrary units) — p=>0.05
N/A N=82 Facilitators and Barriers to Cancer Screening: Stakeholder Perspectives on Implementation
Colorectal Cancer Screening
Primary: Facilitators and Barriers to Implementing Decision Aids, Provider Notifications, and Personal Risk Calculation Using an Electronic Health Record (EHR) to Promote…
Phase 2 N=195 Phase II Randomized Trial of Bethesda Protocol Compared to Cambridge Method for Detection of Early Stage Gastric Cancer in CDH1 Mutation Carriers
Gastric Cancer · Gastric Neoplasms · Gastric Adenocarcinoma
Primary: Proportion of Participants With Improved Sensitivity for Detection of Early-stage Gastric Cancer in CDH1 Germline Mutation Carriers Compared to the Cambridge Method — 1…
N/A N=35 Fiber and Fish Oil Supplements for the Prevention of Colorectal Cancer
Healthy Subject
Primary: Feasibility and Retention for a Trial With Daily Doses of 35 g of Fiber and 6.2 g of EPA +DHA (and Corresponding Comparators) — 14; 15; 1; 1 Participants
N/A N=477 Evaluating Strategies to Present Colon Cancer Screening Information
Colonic Neoplasms · Colorectal Neoplasms · Colonic Diseases
Primary: Intentions to Get Screened for Colon Cancer — 68.64; 65.51; 64.30 units on a 0-100 scale — p=.362
N/A N=61,864 Risk of Cancer Among Pantoprazole Users
Esophagitis
Primary: Incidence Rate of Gastric Cancer — 19.88; 23.73 incidence per 100000 person-years
Phase 2 N=39 Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Gastric Cancer
Gastric Cancer
Primary: Grade 3 or Higher Toxicity Incidence on Step 1 — 65.8 percentage of participants
N/A N=12 Studies in Patients With Low Anterior Resection Syndrome (LARS)
Anterior Resection Syndrome · Bowel Dysfunction
Primary: Change of Anorectal Pressure Assessed With the Fecobionics Device — 9.8 cmH2O
Phase 3 N=15 Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial
Gastric Cancer
Primary: Overall Survival in Patients With Limited Metastatic Gastric Carcinoma: Arm I — 19; 11; 11; 4 Months
Phase 2 N=91 Chemoprevention of Gastric Carcinogenesis
Gastric Cancer · Gastric Intestinal Metaplasia
Primary: The Difference in Cell DNA Damage, Based on Percent Positive Cells, Between Patients Treated With DFMO and Patients Treated With Placebo at 6 Months. — 5.07; 7.32…
N/A N=135 Patient-Centered Cancer Prevention In Chinese Americans
H. Pylori Infection
Primary: Number of Participants With Eradication of H. Pylori (ITT) — 49; 54 Participants